Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin dose comparison for peripheral microvascular dysfunction after NSTEMI
ACTRN12613000575730Phase 4Withdrawn
- Sponsor
- Lyell McEwin Hospital Department of Cardiology
- Start
- Jan 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of rosuvastatin in Non-ST-segment elevation myocardial infarction (NSTEMI) (2 arms), sponsored by Lyell McEwin Hospital Department of Cardiology. Primary endpoint: Change in peripheral subcutaneous microvascular reactivity. Planned start Jan 2016; status: withdrawn.
02
Drugs
rosuvastatin
03
Conditions
Non-ST-segment elevation myocardial infarction (NSTEMI)
Beyond the preview
Go deeper on ACTRN12613000575730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000575730.